<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6778435\results\search\drugs\results.xml">
   <result pre="A/CK/GD/178/04 (H5N1) (GD178) viruses than the commercial neuraminidase (NA) inhibitor" exact="oseltamivir" post="in our prior study. Lycorine demonstrates outstanding antiviral activity"/>
   <result pre="al., 2017; Hu et al., 2017). M2 inhibitors, such as" exact="amantadine" post="and ramantadine, cannot protect the host from virus infection"/>
   <result pre="its amino acid mutation (Wang et al., 2013). To date," exact="oseltamivir" post="is the only commercial drug effective in human, where"/>
   <result pre="antimalarial, anti-parasite, antioxidant, hepatoprotective, analgesic, anti-inflammatory activities, and inhibition of" exact="ascorbic acid" post="synthesis (Kim et al., 2008; Lamoral-Theys et al., 2009;"/>
   <result pre="protein kinase (STK10), and other proteins (8/71) were involved in" exact="adenosine" post="and guanine triphosphatase (ATP and GTP) activity-related pathways; other"/>
   <result pre="found that lycorine exhibits stronger anti-influenza activity against GD178 than" exact="oseltamivir" post="and retains vRNP in the nucleus (He et al.,"/>
   <result pre="hepatocellular carcinomaMolecular Cancer Therapeutics16122711272310.1158/1535-7163.MCT-17-049828974556 Yusuf et al. (2016)YusufMMohamedNMohamadSJanezicDDamodaranKVWahabHA2016H274Y’s effect on" exact="oseltamivir" post="resistance: what happens before the drug enters the binding"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6780377\results\search\drugs\results.xml">
   <result pre="for repressing Flaviviruses. Guanine biosynthesis can be inhibited through antiviral" exact="ribavirin" post="[69]. Dihydroorotate dehydrogenase (DHODH) is a mitochondrial protein that"/>
   <result pre="(HS) mimetic PI88 [80], α- d-glucan [84], GAG [85], and" exact="dextran" post="sulfate (DS, MW &amp;gt; 500,000 Da) [85] are also"/>
   <result pre="(MAPKAPK5) kinase activity and inhibit DENV propagation [108]. GNF-2 and" exact="imatinib" post="inhibit DENV but are mediated by cellular Abl kinases"/>
   <result pre="were non-detectable [142,143,144]. It has been demonstrated that IFN-γ controls" exact="nitric oxide" post="synthase II-mediated nitric oxide production that assists the host"/>
   <result pre="has been demonstrated that IFN-γ controls nitric oxide synthase II-mediated" exact="nitric oxide" post="production that assists the host in resistance against primary"/>
   <result pre="in Patients with Dengue Hemorrhagic FeverFEMS Immunol. Med. Microbiol.20002815115510.1111/j.1574-695X.2000.tb01470.x10799806 145.Neves-SouzaP.C.AzeredoE.L.ZagneS.M.Valls-de-SouzaR.ReisS.R.CerqueiraD.I.NogueiraR.M.KubelkaC.F.Inducible" exact="nitric oxide" post="synthase (iNOS) expression in monocytes during acute Dengue Fever"/>
   <result pre="Huh-7 [176] Isothiazolo[5,4-b] pyridines GAK DENV-2 Huh-7 [177] Sunitinib and" exact="erlotinib" post="AAK1 and GAK DENV-2 Huh7 [178] AR-12 PI3K/JAKT pathway"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6783508\results\search\drugs\results.xml">
   <result pre="treatments. Thirdly, the effect of the histone deactylase (HDAC) inhibitor" exact="vorinostat" post="on HERV expression in CD4+ T cells was analyzed"/>
   <result pre="identified three HERV-9 members (LTR12 elements) that were upregulated by" exact="vorinostat" post="in a dose-dependent manner. The relevance of this finding"/>
   <result pre="and HERV-FRD families were not found to be upregulated by" exact="vorinostat" post="(1). Notably the study by White et al. unlike"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6783926\results\search\drugs\results.xml">
   <result pre="Carlsbad, CA, USA), 1000 units/mL penicillin, and 100 μg/mL of" exact="streptomycin" post="(Invitrogen, Carlsbad, CA, USA). The influenza A reporter PR8-Gluc"/>
   <result pre="11 on each plate) at a 10 mM concentration in" exact="dimethyl sulfoxide" post="(DMSO), leaving columns 1, and 12 with DMSO. The"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6784050\results\search\drugs\results.xml">
   <result pre="of an hour in an artificial membrane feeder when using" exact="lithium" post="heparin-treated rabbit blood, necessitating the use of sodium citrate"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6787251\results\search\drugs\results.xml">
   <result pre="DMEM medium (Gibco) + 1% non-essential amino acids, 5% fetal bovine serum," exact="streptomycin" post="(100 µg per ml), and penicillin (100 U per ml) at"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6788403\results\search\drugs\results.xml">
   <result pre="substitution in the neuraminidase and exhibited highly reduced inhibition by" exact="oseltamivir" post="and peramivir, and one (0.1%) influenza B virus contained"/>
   <result pre="Infect Dis J2000;19:410–7. 10.1097/00006454-200005000-0000510819336 5. HeinonenS, SilvennoinenH, LehtinenP, et al.Early" exact="oseltamivir" post="treatment of influenza in children 1–3 years of age:"/>
   <result pre="Neuraminidase Inhibitor Flu Treatment Investigator Group. Efficacy and safety of" exact="oseltamivir" post="in treatment of acute influenza: a randomised controlled trial.Lancet2000;355:1845–50."/>
   <result pre="Study Group. Efficacy and safety of the oral neuraminidase inhibitor" exact="oseltamivir" post="in treating acute influenza: a randomized controlled trial.JAMA2000;283:1016–24. 10.1001/jama.283.8.101610697061"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6789482\results\search\drugs\results.xml">
   <result pre="viral proteinsJ. Clin. Microbiol.199028268126882177748 19.GernaG.ZipetoD.PareaM.RevelloM.G.SiliniE.PercivalleE.ZavattoniM.GrossiP.MilanesiG.Monitoring of human cytomegalovirus infections and" exact="ganciclovir" post="treatment in heart transplant recipients by determination of viremia,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6789597\results\search\drugs\results.xml">
   <result pre="rashes, and fluids to prevent dehydration in ZIKV-infected patients. However," exact="acetylsalicylic acid" post="and non-steroidal anti-inflammatory drugs (NSAIDs) are contraindicated because of"/>
   <result pre="in pre-clinical evaluation, this drug was dismissed [55]. The prodrug" exact="sofosbuvir" post="is a nucleoside analog that is a RdRp inhibitor"/>
   <result pre="commercially available for the treatment of chronic HCV infection. The" exact="sofosbuvir" post="phosphoramidate prodrug is converted to its triphosphate analog in"/>
   <result pre="inhibitory activity in Vero cells. Therefore, the inhibitory activity of" exact="sofosbuvir" post="varied among different cell types [58]. Interestingly, sequence analysis"/>
   <result pre="sequence analysis of ZIKV isolated from infected cells treated with" exact="sofosbuvir" post="showed higher frequency of mutations compared with untreated cells"/>
   <result pre="receptor 1 (IFN-αR1) blocking antibody [60], therapeutic oral administration of" exact="sofosbuvir" post="with a physiologically relevant dose of 33 mg/kg/day for"/>
   <result pre="toxicity [57]. Importantly, in clinical phase II and III studies," exact="sofosbuvir" post="was found to be clinically safe and efficacious in"/>
   <result pre="men and non-pregnant women to prevent tissue damage. BCX4430, an" exact="adenosine" post="nucleoside analog, is a selective inhibitor of the viral"/>
   <result pre="ZIKV methyltransferase in complex with the pan-methyltransferase inhibitor sinefungin, an" exact="adenosine" post="derivative, originally isolated from Streptomyces griseoleus as a potential"/>
   <result pre="five flavonoids (myricetin, quercetin, luteolin, isorhamnetin, apigenin) and one natural" exact="phenol" post="(curcumin) which were shown to inhibit Zika NS2B-NS3 protease"/>
   <result pre="severe histopathological changes than untreated controls [77]. NS3 helicases display" exact="adenosine" post="triphosphatase (ATPase) and RNA triphosphatase (RTPase) activities. NS3 inhibitors"/>
   <result pre="to explain ribavirin’s antiviral properties including indirect mechanisms such as" exact="inosine" post="monophosphate dehydrogenase inhibition (IMPDH) and immunomodulatory effects as well"/>
   <result pre="infections. Our group and others demonstrated the inhibitory activity of" exact="ribavirin" post="against ZIKV strains of different geographic origins in several"/>
   <result pre="Recent studies have shown that merimepodib (MMPD or VX-497) and" exact="mycophenolic acid" post="(MPA), two IMPDH inhibitors, also inhibit ZIKV-RNA replication in"/>
   <result pre="assay (EC50 = 20.7 μM) [93]. The antiflaviviral activity of" exact="lovastatin" post="was also demonstrated against HCV and DENV [94,95]. In"/>
   <result pre="et al., demonstrated that a short-term parenteral course of high-dose" exact="lovastatin" post="in mice markedly attenuated nervous system injury and, thus,"/>
   <result pre="values of 9.82, 14.2, and 12.36 μM, respectively. In addition," exact="chloroquine" post="was able to partially reverse morphological changes induced by"/>
   <result pre="changes induced by ZIKV in mouse neurospheres [101]. In vitro," exact="chloroquine" post="reduces the number of ZIKV-infected cells, and inhibits virus"/>
   <result pre="multiple neural cell types or inhibit ZIKV replication. Among them," exact="seliciclib" post="(a purine analog) and RGB-286147 inhibited ZIKV infection at"/>
   <result pre="to treat Alzheimer disease such as memantine, MK-801, agmatine, and" exact="ifenprodil" post="were found to prevent neuronal cell death caused by"/>
   <result pre="ameliorate neuronal symptoms during infection. Costa et al. showed that" exact="memantine" post="was very effective at preventing ZIKV-induced neuronal cell death"/>
   <result pre="ZIKV-induced neuronal cell death and neurodegeneration in IFN-α/βR−/−mice [106]. Importantly," exact="memantine" post="is also listed in pregnancy category B drugs by"/>
   <result pre="women and fetus. The World Health Organization (WHO) recommends that" exact="niclosamide" post="may be used during pregnancy as an anthelminthic agent"/>
   <result pre="individual patients in clinical settings, the risk of treatment with" exact="niclosamide" post="in pregnant women who are known to have an"/>
   <result pre="disease progression in the absence of treatment�? (http://www.cdc.gov/parasites/hymenolepis/health_professionals/). In addition," exact="niclosamide" post="and other direct- or indirect-acting agents could be used"/>
   <result pre="al.Inhibition of dengue virus by an ester prodrug of an" exact="adenosine" post="analogAntimicrob. Agents Chemother.2010543255326110.1128/AAC.00397-1020516277 50.FurutaY.TakahashiK.ShirakiK.SakamotoK.SmeeD.F.BarnardD.L.GowenB.B.JulanderJ.G.MorreyJ.D.T-705 (favipiravir) and related compounds: Novel"/>
   <result pre="efficacy against Zika infectionInt. J. Infect. Dis.201755293010.1016/j.ijid.2016.12.01127988410 57.Bullard-FeibelmanK.M.GoveroJ.ZhuZ.SalazarV.VeselinovicM.DiamondM.S.GeissB.J.The FDA-approved drug" exact="sofosbuvir" post="inhibits Zika virus infectionAntivir. Res.201713713414010.1016/j.antiviral.2016.11.02327902933 58.SacramentoC.Q.de MeloG.R.de FreitasC.S.RochaN.HoelzL.V.MirandaM.Fintelman-RodriguesN.MarttorelliA.FerreiraA.C.Barbosa-LimaG.et al.The"/>
   <result pre="infectionAntivir. Res.201713713414010.1016/j.antiviral.2016.11.02327902933 58.SacramentoC.Q.de MeloG.R.de FreitasC.S.RochaN.HoelzL.V.MirandaM.Fintelman-RodriguesN.MarttorelliA.FerreiraA.C.Barbosa-LimaG.et al.The clinically approved antiviral drug" exact="sofosbuvir" post="inhibits Zika virus replicationSci. Rep.201774092010.1038/srep4092028098253 59.PeralesC.DomingoE.Antiviral Strategies Based on"/>
   <result pre="III studiesDig. Liver Dis.201446Suppl. 5S179S18510.1016/j.dld.2014.09.02625458780 62.EyerL.ZouharovaD.SirmarovaJ.FojtikovaM.StefanikM.HaviernikJ.NenckaR.de ClercqE.RuzekD.Antiviral activity of the" exact="adenosine" post="analogue BCX4430 against West Nile virus and tick-borne flavivirusesAntivir."/>
   <result pre="86.BekermanE.EinavS.Infectious disease. Combating emerging viral threatsScience201534828228310.1126/science.aaa377825883340 87.GraciJ.D.CameronC.E.Mechanisms of action of" exact="ribavirin" post="against distinct virusesRev. Med. Virol.200616374810.1002/rmv.48316287208 88.SidwellR.W.HuffmanJ.H.KhareG.P.AllenL.B.WitkowskiJ.T.RobinsR.K.Broad-spectrum antiviral activity of"/>
   <result pre="macrolides during pregnancyAm. J. Obstet Gynecol.2013208221.e1221.e810.1016/j.ajog.2012.12.02323254249 99.Al-BariM.A.A.Targeting endosomal acidification by" exact="chloroquine" post="analogs as a promising strategy for the treatment of"/>
   <result pre="Causes Placental Damage and Fetal DemiseCell20161651081109110.1016/j.cell.2016.05.00827180225 103.KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and" exact="gemcitabine" post="inhibit Zika virus infection in vitro and differentially affect"/>
   <result pre="isorhamnetin, apigenin, curcumin NS2B-NS3 protease inhibitor √ X Niclosamide, and" exact="nitazoxanide" post="NS2B-NS3 protease inhibitor √ X Temoporfin NS2B-NS3 protease inhibitor"/>
   <result pre="Several mechanisms including purine synthesis inhibitor √ √ Merimepodib and" exact="mycophenolic acid" post="Inosine monophosphate dehydrogenase (IMPDH) inhibitors √ X Azathioprine Purine"/>
   <result pre="inhibitor √ X 6-azauridine, 5-fluorouracil Pirimidine synthesis inhibitor √ X" exact="lovastatin" post="HMG-CoA reductase inhibitor √ X Azithromycin Unknown mechanisms of"/>
   <result pre="X PHA-690509 Cyclin-dependent kinase inhibitor √ X MK-801, agmatine, and" exact="ifenprodil" post="Neuronal cell death inhibitor √ X Memantine Neuronal cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6789886\results\search\drugs\results.xml">
   <result pre="1640 supplemented with 50 μM beta-mercaptoethanol, penicillin (100 U/mL, Lonza)," exact="streptomycin" post="(100 μg/mL, Lonza), and 10% foetal bovine serum (FBS;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6797548\results\search\drugs\results.xml">
   <result pre="transmission in mammals.mSphere1:e00003–16. 10.1128/mSphere.00003-1627303732 McNichollI. R.McNichollJ. J. (2001). Neuraminidase inhibitors:" exact="zanamivir" post="and oseltamivir.Ann. Pharmacother.3557–70. 10.1345/aph.1011811197587 NunezI. A.RossT. M. (2019). A"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6798124\results\search\drugs\results.xml">
   <result pre="Eagle’s MEM (EMEM; Lonza) supplemented with 5% NaHCO3, penicillin-streptomycin (Gibco)," exact="l-glutamine" post="(Gibco), and 1% FBS was added to the cells."/>
   <result pre="100 U/ml in EMEM supplemented with 5% NaHCO3, penicillin-streptomycin (Gibco)," exact="l-glutamine" post="(Gibco), and 1% FBS. Also, some cells were infected"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6800501\results\search\drugs\results.xml">
   <result pre="influenza virus M2 proton channel is formed by a single" exact="tryptophan" post="residueJ Biol Chem200227742398803988610.1074/jbc.M20658220012183461 119.TompkinsSMZhaoZSLoCYMisplonJALiuTYeZHoganRJWuZBentonKATumpeyTMEpsteinSLMatrix protein 2 vaccination and protection"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6800565\results\search\drugs\results.xml">
   <result pre="doi:10.1016/j.oftal.2012.07.00723473088 5.ShiueyY, AmbatiBK, AdamisAP. A randomized, double-masked trial of topical" exact="ketorolac" post="versus artificial tears for treatment of viral conjunctivitis. Ophthalmology."/>
   <result pre="6.LyraAFV, BastosLC, LimaRCS, MaranhãoLVL, ArantesTE. Artificial tears alone versus 0.45%" exact="ketorolac" post="tromethamine with artificial tears for the treatment of acute"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6805736\results\search\drugs\results.xml">
   <result pre="A virus. Guangdong Medical Journal30, 703–705. 23.HungIFet al. (2016) Topical" exact="imiquimod" post="before intradermal trivalent influenza vaccine for protection against heterologous"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6814692\results\search\drugs\results.xml">
   <result pre="weeks after the second immunization, mice were anesthetized using sodium" exact="pentobarbital" post="(10 mg/mL) at a dose of 60 mg/kg of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6818521\results\search\drugs\results.xml">
   <result pre="addition to early treatment with oseltamivir, POCT enabled effective post-contact" exact="oseltamivir" post="prophylaxis for close contacts, for example, those living in"/>
   <result pre="17PuhakkaT, MäkeläMJ, MalmströmK, et al.The common cold: effects of intranasal" exact="fluticasone" post="propionate treatment. J Allergy Clin Immunol1998;101:726–31. 10.1016/S0091-6749(98)70301-X9648698 18JokelaP, VuorinenT,"/>
   <result pre="24LeeN, HuiDSC, ZuoZ, et al.A prospective intervention study on higher-dose" exact="oseltamivir" post="treatment in adults hospitalized with influenza A and B"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6819614\results\search\drugs\results.xml">
   <result pre="the phage/bacteria ratio in lactic acid bacteria known to produce" exact="dopamine" post="and regulate intestinal permeability, both major factors implicated in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6823455\results\search\drugs\results.xml">
   <result pre="substitution medium (Gibco Invitrogen) supplemented with 0.6 µg/ml penicillin and 60 µg/ml" exact="streptomycin" post="in the presence of 10 ng/ml human granulocyte-macrophage colony-stimulating factor"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6827708\results\search\drugs\results.xml">
   <result pre="travel history, rash, and fever, he was started on empiric" exact="doxycycline" post="therapy for presumed arthropod-related illness. Serology for tick-borne illness"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6832137\results\search\drugs\results.xml">
   <result pre="of flu antiviral drugs include M2 ion channel blockers (e.g.," exact="amantadine" post="and rimantadine) and neuraminidase inhibitors (e.g., zanamivir, oseltamivir). Early"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6832241\results\search\drugs\results.xml">
   <result pre="fetal bovine serum (FBS), and 1% PSG (penicillin, 100 units/mL;" exact="streptomycin" post="100 μg/mL; l-glutamine, 2 mM) at 37 °C with"/>
   <result pre="(PBS) containing 0.3% bovine albumin (BA) and 1% penicillin and" exact="streptomycin" post="(PS) (PBS/BA/PS). After 1 h viral adsorption at room"/>
   <result pre="with 0.3% BA, 1% PSG, and 1 μg/mL of N-tosyl-" exact="l-phenylalanine" post="chloromethyl ketone (TPCK)-treated trypsin (Sigma). Viral titers were determined"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6832525\results\search\drugs\results.xml">
   <result pre="sofosbuvir’s inhibitory effects on YFV replication: in a mouse model," exact="sofosbuvir" post="was able to decrease mortality and weight loss associated"/>
   <result pre="(mAb) therapies [44]. Antiviral mAbs represent viable therapeutic options, including" exact="palivizumab" post="(marketed as Synagis), which is licensed for use against"/>
   <result pre="feverAntivir. Res.20087811612410.1016/j.antiviral.2007.10.00918061688 34.SacramentoC.Q.de MeloG.R.de FreitasC.S.RochaN.HoelzL.V.B.MirandaM.Fintelman-RodriguesN.MarttorelliA.FerreiraA.C.Barbosa-LimaG.et al.The clinically approved antiviral drug" exact="sofosbuvir" post="inhibits Zika virus replicationSci. Rep.201774092010.1038/srep4092028098253 35.XuH.-T.Colby-GerminarioS.P.HassounahS.A.FogartyC.OsmanN.PalanisamyN.HanY.OliveiraM.QuanY.WainbergM.A.Evaluation of Sofosbuvir (β-D-2’-deoxy-2’-α-fluoro-2’-β-C-methyluridine)"/>
   <result pre="Rep.20177634510.1038/s41598-017-06612-228740124 36.De FreitasC.S.HigaL.M.SacramentoC.Q.FerreiraA.C.ReisP.A.DelvecchioR.MonteiroF.L.Barbosa-LimaG.James WestgarthH.VieiraY.R.et al.Yellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Negl. Trop. Dis.201913e000707210.1371/journal.pntd.000707230699122"/>
   <result pre="in vitro and in vivoPLoS Negl. Trop. Dis.201913e000707210.1371/journal.pntd.000707230699122 37.YinZ.ChenY.-L.SchulW.WangQ.-Y.GuF.DuraiswamyJ.KondreddiR.R.NiyomrattanakitP.LakshminarayanaS.B.GohA.et al.An" exact="adenosine" post="nucleoside inhibitor of dengue virusProc. Natl. Acad. Sci. USA2009106204352043910.1073/pnas.090701010619918064"/>
   <result pre="immature flavivirus particlesEMBO J.2003222604261310.1093/emboj/cdg27012773377 60.ReschB.Product review on the monoclonal antibody" exact="palivizumab" post="for prevention of respiratory syncytial virus infectionHum. Vaccin. Immunother.2017132138214910.1080/21645515.2017.133761428605249"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6834095\results\search\drugs\results.xml">
   <result pre="spinal cord were normal. The patient underwent pulse therapy with" exact="dexamethasone" post="for five days, without improvement in the condition and"/>
   <result pre="She presented respiratory insufficiency, even after new pulse therapy with" exact="methylprednisolone" post="for five days, being intubated, requiring continuous mechanical ventilatory"/>
   <result pre="wherein repeated use of immunotherapeutics with human endovenous Ig, corticosteroids," exact="cyclophosphamide" post="and plasmapheresis sessions were not successful. The authors have"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6834195\results\search\drugs\results.xml">
   <result pre="to inhibit EV-A71 infections by blocking the polymerase such as" exact="ribavirin" post="and DTriP-22 [83,84]. 10. Risk Factors for Severity in"/>
   <result pre="by Decreasing Viral ReplicationJ. Infect. Dis.200819785485710.1086/52732618279075 84.ZhangH.-P.WangL.QianJ.-H.CaiK.ChenY.-H.ZhangQ.-L.YuH.-J.Efficacy and safety of" exact="ribavirin" post="aerosol in children with hand-foot-mouth diseaseZhongguo Dang Dai Er"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6838024\results\search\drugs\results.xml">
   <result pre="et al., 2018). Non-specific treatment with pegylated interferons along with" exact="ribavirin" post="is recommended in rare instances for severe cases because"/>
   <result pre="serum (FBS) (Invitrogen) and 100 U/ml penicillin and 100 mg/ml" exact="streptomycin" post="(Sigma). Construction of Recombinant Plasmids Coding sequence of HEV"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6839921\results\search\drugs\results.xml">
   <result pre="by phagocytic cells results in intracellular release of the encapsulated" exact="clodronate" post="which is cytotoxic (Van Rooijen, 1989). At 42 hr"/>
   <result pre="3C). Similar results were observed following pretreatment of mice with" exact="dextran" post="sulfate (DS), another SR ligand (Platt and Gordon, 1998)"/>
   <result pre="WT C57BL/6 mice were treated i.v. with 200 μg of" exact="dextran" post="or dextran sulfate 5 min prior to inoculation with"/>
   <result pre="mice were treated i.v. with 200 μg of dextran or" exact="dextran" post="sulfate 5 min prior to inoculation with the indicated"/>
   <result pre="WT C57BL/6 mice were treated i.v. with PBS liposomes or" exact="clodronate" post="liposomes 42 hr prior to i.v. inoculation with CHIKV"/>
   <result pre="pre-treatment of mice with the SR competitive inhibitors poly(I) and" exact="dextran" post="sulfate (Platt and Gordon, 1998), supporting a role for"/>
   <result pre="in clearance of these alphaviruses from the circulation. Poly(I) and" exact="dextran" post="sulfate are known ligands for the class A scavenger"/>
   <result pre="and Gorelkin, 1975) and that depletion of phagocytic cells with" exact="clodronate" post="liposomes resulted in a higher magnitude and duration of"/>
   <result pre="subcutaneous CHIKV infection of mice (Gardner et al., 2010). Similarly," exact="clodronate" post="liposome depletion of phagocytic cells enhanced WNV viremia and"/>
   <result pre="animals were humanely euthanized at defined endpoints by exposure to" exact="isoflurane" post="vapors followed by thoracotomy. Cells Cell lines were obtained"/>
   <result pre="or poly(C) (Sigma 26936-41-4 and 26936-40-3) or 200 μg of" exact="dextran" post="or dextran sulfate (Sigma 31392 and D6001) 5 min"/>
   <result pre="(Sigma 26936-41-4 and 26936-40-3) or 200 μg of dextran or" exact="dextran" post="sulfate (Sigma 31392 and D6001) 5 min prior to"/>
   <result pre="the time of termination, mice were euthanized through inhalation of" exact="isoflurane" post="vapors, followed by thoracotomy, and serum was collected. In"/>
   <result pre="which the inoculum was removed and an overlay of 0.5%" exact="methylcellulose" post="in MEM-alpha with 10% FBS was added to the"/>
   <result pre="animals were humanely euthanized at defined endpoints by exposure to" exact="isoflurane" post="vapors followed by thoracotomy. Additional files 10.7554/eLife.49163.026Supplementary file 1."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6841724\results\search\drugs\results.xml">
   <result pre="effect of flavonoids seems to occur through interactions between the" exact="phenol" post="rings of flavonoids and viral proteins and/or RNA, or"/>
   <result pre="in DMEM high glucose supplemented with 100 IU/mL penicillin, 100 µg/mL" exact="streptomycin" post="and 10% FBS. Human embryonic stem cell line (NKX2-5eGFP/whESC)"/>
   <result pre="(Dallas, TX, USA), prepared in a 50 mM stock solution in" exact="dimethyl sulfoxide" post="(DMSO, Sigma-Aldrich, St. Louis, MO, USA) and then diluted"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6844409\results\search\drugs\results.xml">
   <result pre="of engraftment of modified cells could be achieved by including" exact="cyclophosphamide" post="treatment. Despite low numbers of engineered cells in treated"/>
   <result pre="University, Atlanta, USA) presented a study on the use of" exact="fingolimod" post="at the time of ART initiation. This compound is"/>
   <result pre="animals followed to determine time to viral rebound. As expected," exact="fingolimod" post="induced peripheral lymphopenia. Interestingly, this did not influence plasma"/>
   <result pre="mice that had been xenografted with human hepatocytes. Combination with" exact="entecavir" post="(ETV) showed synergistic action with delayed viral rebound, ranging"/>
   <result pre="lymph nodes. PLoS Pathog2018; 14(2): e1006902. 73.CohenJA, BarkhofF, ComiGet al.Oral" exact="fingolimod" post="or intramuscular interferon for relapsing multiple sclerosis. N Engl"/>
   <result pre="402– 415.20089954 74.KapposL, RadueEW, O’ConnorPet al.A placebo-controlled trial of oral" exact="fingolimod" post="in relapsing multiple sclerosis. N Engl J Med2010; 362(5):"/>
   <result pre="138(2): 682– 693, 693.19800335 80.GaneE, VerdonDJ, BrooksAEet al.Anti-PD-1 blockade with" exact="nivolumab" post="with and without therapeutic vaccination for virally suppressed chronic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6854512\results\search\drugs\results.xml">
   <result pre="editing. The transfected cells were selected by incubating with 2 μg/ml" exact="puromycin" post="for 72 h, and then isogenic cell lines were isolated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6858468\results\search\drugs\results.xml">
   <result pre="vaccine for RSV has been available. The RSV-specific monoclonal antibody" exact="palivizumab" post="has been advocated for use as prophylaxis in high-risk"/>
   <result pre="vaccines or drugs have been developed against these viruses, except" exact="palivizumab" post="for RSV prophylaxis [18]. Thus, additional research must be"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6862093\results\search\drugs\results.xml">
   <result pre="have yet to be identified. In relation to stockpiling of" exact="oseltamivir" post="in planning for potential simultaneous epidemics of different virus"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6863932\results\search\drugs\results.xml">
   <result pre="A/Cal and delivered s.c. For infections, mice were anesthetized using" exact="isoflurane" post="and infected i.n. with 100 μl influenza virus or"/>
   <result pre="protocols, and blood sampling) were conducted after sedating animals with" exact="ketamine" post="chlorhydrate (Rhône-Mérieux, Lyon, France, 10 mg/kg). Mouse studies in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6868920\results\search\drugs\results.xml">
   <result pre="of 611 aa, is a RNA-dependent RNA polymerase and terminal" exact="adenosine" post="transferase, responsible for synthesis of different viral RNAs and"/>
   <result pre="35KhanMSanthoshSRTiwariMLakshmana RaoPVParidaMAssessment of in vitro prophylactic and therapeutic efficacy of" exact="chloroquine" post="against Chikungunya virus in vero cellsJ Med Virol201082817–2420336760 36KiatTSPippenRYusofRIbrahimHKhalidNRahmanNAInhibitory"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6872174\results\search\drugs\results.xml">
   <result pre="For infections and blood collections, mice were anesthetized using either" exact="isoflurane" post="inhalation or a ketamine/xylazine (10 and 1 mg/ml, respectively)"/>
   <result pre="TakahashiS, TazumaS, et al.Evolution of hepatitis C virus quasispecies during" exact="ribavirin" post="and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy. Intervirology. 2006;49:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6874238\results\search\drugs\results.xml">
   <result pre="quarters twice daily with F10 antiseptic solution (1:250 dilution) containing" exact="benzalkonium chloride" post="and polyhexanide. Clinical surveillance performed on staff members of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6883514\results\search\drugs\results.xml">
   <result pre="were measured according to the local laboratory standard (Düsseldorf: turbidimetric," exact="benzethonium chloride" post="method, cobas® 8000, C701, Fa. Roche Diagnostics, Mannheim for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6890994\results\search\drugs\results.xml">
   <result pre="(animal protocol number LVD26). All procedures were carried out under" exact="ketamine" post="anesthesia by trained personnel with veterinary staff supervision. This"/>
   <result pre="Sci Transl Med9:eaao4163. doi:10.1126/scitranslmed.aao4163.29237759 59.AndersonJF, RahalJJ2002Efficacy of interferon alpha-2b and" exact="ribavirin" post="against West Nile virus in vitro. Emerg Infect Dis8:107–108."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6892364\results\search\drugs\results.xml">
   <result pre="The acquisition of drug resistance, for example malaria parasites to" exact="chloroquine" post="or the mosquito vector to insecticide, is one of"/>
   <result pre="mutation patterns in K13 gene [26], the gene related to" exact="artemisinin" post="resistance, that were in concordance with a major paper"/>
   <result pre="the Mekong region [27]. Nevertheless, the mutations conferring resistance to" exact="chloroquine" post="were similar in these three regions. This method applies"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6892822\results\search\drugs\results.xml">
   <result pre="CRL-2936) were grown in minimal essential medium supplemented with 2 mM" exact="l-glutamine" post="and 10 % (v/v) fetal bovine serum. DF-1 (ATCC"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893414\results\search\drugs\results.xml">
   <result pre="promising drug for patients with ZIKV infection, particularly pregnant women." exact="erythromycin" post="estolate ZIKV viral entry inhibitor inactivator 1. Introduction Zika"/>
   <result pre="library consisting of FDA-approved medical drugs with good safety, and" exact="erythromycin" post="estolate (Ery-Est), which could be safely used by pregnant"/>
   <result pre="the macrolide antibiotics, is the lauryl sulfate ester of propionyl" exact="erythromycin" post="(Ery) (Figure 1A), and it has commonly been used"/>
   <result pre="studied to treat a wide spectrum of viruses. For example," exact="clarithromycin" post="and the macrolide therapy have been utilized to treat"/>
   <result pre="and Middle East respiratory syndrome coronavirus (MERS-CoV) infection respectively, and" exact="ivermectin" post="and azithromycin (Azi) were identified to effectively inhibit ZIKV"/>
   <result pre="East respiratory syndrome coronavirus (MERS-CoV) infection respectively, and ivermectin and" exact="azithromycin" post="(Azi) were identified to effectively inhibit ZIKV infection [17,18,19,20,21,22,23]."/>
   <result pre="C6/36 cells. 2.2. Compounds Erythromycin estolate (Ery-Est), Erythromycin (Ery), and" exact="azithromycin" post="(Azi) powders were bought from Santa Cruz Biotechnology, Inc."/>
   <result pre="time of our study. Besides, some macrolide antibiotics, such as" exact="azithromycin" post="and ivermectin, have been previously found to effectively inhibit"/>
   <result pre="have been previously found to effectively inhibit ZIKV infection. Moreover," exact="azithromycin" post="was reported to not only inhibit ZIKV in vitro,"/>
   <result pre="Origins, Pathological Action, and Treatment StrategiesFront. Microbiol.20189325210.3389/fmicb.2018.0325230666246 44.CroteauD.BergeronM.G.LeBelM.Pharmacokinetic advantages of" exact="erythromycin" post="estolate over ethylsuccinate as determined by high-pressure liquid chromatographyAntimicrob."/>
   <result pre="Rev.2007Cd00440410.1002/14651858.CD004404.pub317636756 46.LangleyJ.M.HalperinS.A.BoucherF.D.SmithB.Azithromycin is as effective as and better tolerated than" exact="erythromycin" post="estolate for the treatment of pertussisPediatrics.2004114e96e10110.1542/peds.114.1.e9615231980 47.Raynes-GreenowC.H.RobertsC.L.BellJ.C.PeatB.GilbertG.L.Antibiotics for ureaplasma"/>
   <result pre="fetal disease in miceNature201654044344710.1038/nature2056427819683 Figure 1 The molecular formula of" exact="erythromycin" post="estolate (Ery-Est) and Ery and their inhibitory activity against"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893532\results\search\drugs\results.xml">
   <result pre="this single substitution has been demonstrated to reduce susceptibility to" exact="oseltamivir" post="and zanamivir [36]. Shanghai/2013(H7N9) NA gained a substitution of"/>
   <result pre="substitution has been demonstrated to reduce susceptibility to oseltamivir and" exact="zanamivir" post="[36]. Shanghai/2013(H7N9) NA gained a substitution of the amino"/>
   <result pre="acids 69–73: Increased virulence in mice [33] Reduced susceptibility to" exact="oseltamivir" post="and zanamivir [36] Mammalian host adaptation [37] Lack of"/>
   <result pre="Increased virulence in mice [33] Reduced susceptibility to oseltamivir and" exact="zanamivir" post="[36] Mammalian host adaptation [37] Lack of PDZ domain"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893760\results\search\drugs\results.xml">
   <result pre="virus inhibitory action of 2-(alpha-hydroxybenzyl)-benzimidazole and guanidine HClVirology19621843944710.1016/0042-6822(62)90034-X13990297 152.RhodenE.NixW.A.WeldonW.C.SelvaranganR.Antifungal azoles" exact="itraconazole" post="and posaconazole exhibit potent in vitro antiviral activity against"/>
   <result pre="action of 2-(alpha-hydroxybenzyl)-benzimidazole and guanidine HClVirology19621843944710.1016/0042-6822(62)90034-X13990297 152.RhodenE.NixW.A.WeldonW.C.SelvaranganR.Antifungal azoles itraconazole and" exact="posaconazole" post="exhibit potent in vitro antiviral activity against clinical isolates"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893791\results\search\drugs\results.xml">
   <result pre="evade the innate immunity control by taking advantage of the" exact="adenosine" post="deaminase acting on RNA 1 (ADAR1), an IFN-stimulated gene"/>
   <result pre="(ADAR1), an IFN-stimulated gene that binds double-stranded RNA and converts" exact="adenosine" post="to inosine by deamination [108]. The biased hypermutations in"/>
   <result pre="IFN-stimulated gene that binds double-stranded RNA and converts adenosine to" exact="inosine" post="by deamination [108]. The biased hypermutations in M (and"/>
   <result pre="nucleoside by the viral RNA polymerase [208]. The use of" exact="ribavirin" post="and immune serum globulin seems to decrease respiratory symptoms"/>
   <result pre="protocol and doses recommended to treat patients. IFN-α, ribavirin, and" exact="inosine" post="pranobex are also used for SSPE treatment, with relative"/>
   <result pre="A recent study suggests also that continuous intraventricular administration of" exact="ribavirin" post="and interferon-α in CSF by using a subcutaneous infusion"/>
   <result pre="using a subcutaneous infusion pump, combined with oral administration of" exact="inosine" post="pranobex, could limit the progression of SSPE [214]. Intrathecal"/>
   <result pre="common treatment used nowadays [215,216]. Isoprinosine is a derivative of" exact="inosine" post="and aims at blocking viral replication, probably through an"/>
   <result pre="severe cases of measles, the combination of vitamin A with" exact="ribavirin" post="treatment can also decrease the morbidity [226]. At the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893968\results\search\drugs\results.xml">
   <result pre="of 5c and 5d compounds were prepared by dissolving in" exact="dimethyl sulfoxide" post="(DMSO), and the working concentration was prepared by further"/>
   <result pre="viruses replication by antiviral compounds: synergistic effect of interferon-alpha and" exact="ribavirin" post="combination. Antiviral Res.2004, 61, 111–117. 10.1016/j.antiviral.2003.09.005.14670584 DeloguI.; de LamballerieX.Chikungunya"/>
   <result pre="Antiviral Res.2004, 61, 111–117. 10.1016/j.antiviral.2003.09.005.14670584 DeloguI.; de LamballerieX.Chikungunya disease and" exact="chloroquine" post="treatment. J. Med. Virol.2011, 83, 1058–1059. 10.1002/jmv.22019.21503920 DeloguI.; PastorinoB.;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6904267\results\search\drugs\results.xml">
   <result pre="fusion protein. Transformed cells were cultured in Luria-Bertani medium containing" exact="ampicillin" post="at 37°C, and recombinant expression was induced with 0.6"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6904818\results\search\drugs\results.xml">
   <result pre="1 Rilpivirine Inhibits ZIKV by Blocking Viral RdRp (A) Proposed" exact="rilpivirine" post="binding site on ZIKV RdRp. ZIKV NS5 (PDB: 5TMH)15"/>
   <result pre="PyMOL. (B) In vivo efficacy. Treatment of ZIKV-infected mice with" exact="rilpivirine" post="suppressed viral replication and prevented animal death. First, Sariyer"/>
   <result pre="ZIKV infection of astrocytes as a screening assay, they identified" exact="rilpivirine" post="as a ZIKV inhibitor from eight FDA-approved HIV nucleoside"/>
   <result pre="killing of non-tumor cells. It remains to be tested if" exact="rilpivirine" post="also inhibits closely related flaviviruses, such as dengue, yellow"/>
   <result pre="viruses. Nevertheless, the authors have established the antiviral activity of" exact="rilpivirine" post="against ZIKV in cell culture. Second, Sariyer et al.2"/>
   <result pre="et al.2 provided five lines of evidence to support that" exact="rilpivirine" post="targets ZIKV RdRp (Figure 1A). (1) Computational docking suggests"/>
   <result pre="targets ZIKV RdRp (Figure 1A). (1) Computational docking suggests that" exact="rilpivirine" post="may bind to the palm site of RdRp protein."/>
   <result pre="site of RdRp protein. (2) Differential scanning fluorimetry showed that" exact="rilpivirine" post="binds to recombinant RdRp with a KD of 100"/>
   <result pre="cells, but not the 14-amino acid mutant protein, competed for" exact="rilpivirine" post="binding and thus alleviated compound-mediated antiviral activity. Although these"/>
   <result pre="improved potency. (2) The selection of ZIKV variants resistant to" exact="rilpivirine" post="will identify mutations that are likely mapped to the"/>
   <result pre="Third, Sariyer et al.2 demonstrated the in vivo efficacy of" exact="rilpivirine" post="in a ZIKV interferon α/β receptor (IFNAR)−/− mouse (type"/>
   <result pre="knockout) model (Figure 1B). Treatment of ZIKV-infected IFNAR−/− mice with" exact="rilpivirine" post="reduced organ viral burden and weight loss, improved clinical"/>
   <result pre="caused significant inflammation and abundant apoptotic/necrotic cell damage. Treatment with" exact="rilpivirine" post="reduced the levels of viral RNA in the brain"/>
   <result pre="but it did not eliminate inflammation. These results indicate that" exact="rilpivirine" post="suppressed viral replication and disease development. However, it was"/>
   <result pre="better in vivo efficacy. Nevertheless, the in vivo potency of" exact="rilpivirine" post="seems better than sofosbuvir, a hepatitis C virus (HCV)"/>
   <result pre="(HCV) nucleoside drug that was reported with anti-ZIKV activity.9 Specifically," exact="rilpivirine" post="completely protected ZIKV-infected mice from death, whereas sofosbuvir and"/>
   <result pre="activity.9 Specifically, rilpivirine completely protected ZIKV-infected mice from death, whereas" exact="sofosbuvir" post="and other nucleoside inhibitors only conferred partial protection.10 The"/>
   <result pre="readily advanced to clinical trials for the new indication.11 As" exact="rilpivirine" post="inhibits HIV-1 and ZIKV with EC50 in the single-digit"/>
   <result pre="to ensure clinical efficacy in patients. To achieve this goal," exact="rilpivirine" post="analogs previously synthesized during lead optimization could be tested"/>
   <result pre="with better potency for ZIKV may be identified from the" exact="rilpivirine" post="analogs. Meanwhile, efforts could be made to solve the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6906739\results\search\drugs\results.xml">
   <result pre="death as the readout. We discovered that the neurological drug" exact="ifenprodil" post="and the anticancer drug flavopiridol could effectively ameliorate murine"/>
   <result pre="tested 10 in an H5N1-induced-ALI mouse model. The neurological drug" exact="ifenprodil" post="and the anticancer drug flavopiridol markedly decreased leukocyte infiltration"/>
   <result pre="to leukocyte migration and lung injury. These results suggest that" exact="ifenprodil" post="and flavopiridol represent novel remedies against potential H5N1 epidemics"/>
   <result pre="death as the readout. We discovered that the neurological drug" exact="ifenprodil" post="and the anticancer drug flavopiridol could effectively ameliorate murine"/>
   <result pre="in addition to the traditional indications. KEYWORDS H5N1 lung injury" exact="ifenprodil" post="flavopiridol drug repurposing genomewide RNAi H5N1 Funding Ministry of"/>
   <result pre="tissue from H5N1-infected C57BL/6 mice treated by intraperitoneal injection with" exact="ifenprodil" post="(no. 42), flavopiridol (no. 67), or vehicle. In vitro"/>
   <result pre="(G) Kaplan-Meier survival curves of H5N1-infected C57BL/6 mice treated with" exact="ifenprodil" post="(no. 42), flavopiridol (no. 67), or vehicle by intraperitoneal"/>
   <result pre="decreased the number of infiltrating cells in mouse lung tissues:" exact="glyburide" post="(no. 15), bupivacaine (no. 31), ifenprodil (no. 42), 4-(2-aminoethyl)"/>
   <result pre="of infiltrating cells in mouse lung tissues: glyburide (no. 15)," exact="bupivacaine" post="(no. 31), ifenprodil (no. 42), 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF)"/>
   <result pre="in mouse lung tissues: glyburide (no. 15), bupivacaine (no. 31)," exact="ifenprodil" post="(no. 42), 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF) (no. 47), flavopiridol"/>
   <result pre="42), 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF) (no. 47), flavopiridol (no. 67)," exact="diazoxide" post="(no. 97), diflunisal (no. 101), and vemurafenib (no. 104)"/>
   <result pre="fluoride (AEBSF) (no. 47), flavopiridol (no. 67), diazoxide (no. 97)," exact="diflunisal" post="(no. 101), and vemurafenib (no. 104) (Fig. 2B, C,"/>
   <result pre="flavopiridol (no. 67), diazoxide (no. 97), diflunisal (no. 101), and" exact="vemurafenib" post="(no. 104) (Fig. 2B, C, and E). The following"/>
   <result pre="reduced lung injury scores in animals: ifenprodil, AEBSF, flavopiridol, and" exact="diazoxide" post="(Fig. 2B and D; see also Fig. S4B). Both"/>
   <result pre="diazoxide (Fig. 2B and D; see also Fig. S4B). Both" exact="ifenprodil" post="treatment and flavopiridol treatment ameliorated lung edema by decreasing"/>
   <result pre="during the response to H5N1 virus infection and found that" exact="ifenprodil" post="or flavopiridol significantly decreased the levels of neutrophils, natural"/>
   <result pre="in H5N1 virus-infected mouse lung tissues (Fig. S5). Notably, both" exact="ifenprodil" post="treatment and flavopiridol treatment significantly increased the survival rate"/>
   <result pre="virus-infected mice (Fig. 2G). The weight loss of mice administered" exact="ifenprodil" post="or flavopiridol was recovered at the second week after"/>
   <result pre="10 nonhormonal drugs can ameliorate ALI in H5N1-infected mice, with" exact="ifenprodil" post="and flavopiridol being the most effective. 10.1128/mSystems.00431-19.4FIG S4In vivo"/>
   <result pre="(E) Body weight changes in H5N1-infected C57BL/6 mice treated with" exact="ifenprodil" post="(no. 42), flavopiridol (no. 67), or vehicle by intraperitoneal"/>
   <result pre="staining from H5N1-infected C57BL/6 mice (n = 3 to 5) treated with" exact="ifenprodil" post="(no. 42), flavopiridol (no. 67), or vehicle by intraperitoneal"/>
   <result pre="RNA sequencing (RNA-Seq) analysis of the lung tissue showed that" exact="ifenprodil" post="and flavopiridol alleviated cytokine storm in H5N1-infected mice (Fig."/>
   <result pre="the levels of 23 cytokines/chemokines in plasma from mice administered" exact="ifenprodil" post="or flavopiridol. Overall, ifenprodil treatment and flavopiridol treatment significantly"/>
   <result pre="cytokines/chemokines in plasma from mice administered ifenprodil or flavopiridol. Overall," exact="ifenprodil" post="treatment and flavopiridol treatment significantly decreased the measured levels"/>
   <result pre="S6C to H). Our results suggest that these drugs, especially" exact="ifenprodil" post="and flavopiridol, can attenuate the excessive inflammation caused by"/>
   <result pre="levels in lung tissues of H5N1-infected C57BL/6 mice treated with" exact="ifenprodil" post="(no. 42) (A), flavopiridol (no. 67) (B), or vehicle."/>
   <result pre="and chemokines in plasma from H5N1-infected C57BL/6 mice treated with" exact="ifenprodil" post="(no. 42), flavopiridol (no. 67), or vehicle. Blood samples"/>
   <result pre="chemokines in H5N1-infected C57BL/6 mice (n = 3 to 5) treated with" exact="ifenprodil" post="(no. 42) (A), flavopiridol (no. 67) (B), or vehicle."/>
   <result pre="receptors in H5N1-infected C57BL/6 mice (n = 3 to 5) treated with" exact="glyburide" post="(no. 15) (C), bupivacaine (no. 31) (D), AEBSF (no."/>
   <result pre="mice (n = 3 to 5) treated with glyburide (no. 15) (C)," exact="bupivacaine" post="(no. 31) (D), AEBSF (no. 47) (E), diazoxide (no."/>
   <result pre="15) (C), bupivacaine (no. 31) (D), AEBSF (no. 47) (E)," exact="diazoxide" post="(no. 97) (F), diflunisal (no. 101) (G), vemurafenib (no."/>
   <result pre="31) (D), AEBSF (no. 47) (E), diazoxide (no. 97) (F)," exact="diflunisal" post="(no. 101) (G), vemurafenib (no. 104) (H), or vehicle."/>
   <result pre="47) (E), diazoxide (no. 97) (F), diflunisal (no. 101) (G)," exact="vemurafenib" post="(no. 104) (H), or vehicle. Blood samples were collected"/>
   <result pre="sequencing data from lung tissues of H5N1-infected mice treated with" exact="ifenprodil" post="and analyzed biological processes and pathways influenced by ifenprodil"/>
   <result pre="with ifenprodil and analyzed biological processes and pathways influenced by" exact="ifenprodil" post="compared to vehicle control mice. We found that ifenprodil"/>
   <result pre="by ifenprodil compared to vehicle control mice. We found that" exact="ifenprodil" post="influenced the immune response and neurophysiological processes in the"/>
   <result pre="(Fig. 4A). Nine of the top 10 pathways of the" exact="ifenprodil" post="treatment group were linked to the immune response (Fig."/>
   <result pre="lung diseases as well as to traditional neuropathic indications of" exact="ifenprodil" post="(Fig. 4C; see also Table S4 in the supplemental"/>
   <result pre="(22, 23), our study revealed for the first time that" exact="ifenprodil" post="is effective in avian influenza A H5N1 virus infection"/>
   <result pre="lung injury. FIG 4 Functional processes and pathways influenced by" exact="ifenprodil" post="and flavopiridol in H5N1-infected mice. (A and B) GO"/>
   <result pre="B) GO term (biological process) enrichment of DEGs associated with" exact="ifenprodil" post="(no. 42) treatment (A) or flavopiridol (no. 67) treatment"/>
   <result pre="lung diseases in the top 10 enriched pathways associated with" exact="ifenprodil" post="(no. 42) treatment (C) or flavopiridol (no. 67) treatment"/>
   <result pre="systemic lupus erythematosus; NETosis, neutrophil extracellular trap-associated cell death; PR," exact="progesterone" post="receptor; ERK, extracellular signal-regulated kinase; PI3K, phosphatidylinositol 3-kinase; MAPK,"/>
   <result pre="10.1128/mSystems.00431-19.10TABLE S4Traditional/lung disease-related objects in the top 10 pathways for" exact="ifenprodil" post="(no. 42) and flavopiridol (no. 67) administration. Download Table"/>
   <result pre="ameliorated ALI in H5N1-infected mice. We identified the neurological drug" exact="ifenprodil" post="and the anticancer drug flavopiridol as potential novel effective"/>
   <result pre="influenza A H5N1 virus-infected lung injury. The mechanisms by which" exact="ifenprodil" post="and flavopiridol ameliorate lung injury and improve the survival"/>
   <result pre="influenza A virus-induced ALI (29, 30). We found that both" exact="ifenprodil" post="and flavopiridol significantly decreased the number of infiltrating cells"/>
   <result pre="to disease fatal outcomes (31, 32). In our study, both" exact="ifenprodil" post="and flavopiridol alleviated cytokine storm, as they significantly decreased"/>
   <result pre="conducted bioinformatic analysis, which showed that the genes influenced by" exact="ifenprodil" post="or flavopiridol administration were highly clustered in GO functional"/>
   <result pre="From these collective results, we speculated that the impact of" exact="ifenprodil" post="and flavopiridol on the immune response contributes to the"/>
   <result pre="and to improvement in mouse survival. However, the efficacy of" exact="ifenprodil" post="and flavopiridol for the treatment of H5N1-induced ALI also"/>
   <result pre="were not infected with H5N1. Negative-control cultures were treated with" exact="dimethyl sulfoxide" post="(DMSO). Drugs that significantly improved the viability of H5N1-infected"/>
   <result pre="infected with live H5N1 virus (106 TCID50) and administered vehicle," exact="ifenprodil" post="(20 mg/kg/body weight, intraperitoneally), or flavopiridol (5 mg/kg, intraperitoneally) at 4"/>
   <result pre="(9 to 10 mice per group). Mice were administered vehicle," exact="ifenprodil" post="(20 mg/kg, intraperitoneally), or flavopiridol (5 mg/kg, intraperitoneally) at 24 h"/>
   <result pre="JacobsG, MaJ, SchwartzGK, Abou-AlfaGK2012A nonrandomized, phase II study of sequential" exact="irinotecan" post="and flavopiridol in patients with advanced hepatocellular carcinoma. Gastrointest"/>
   <result pre="flavopiridol given as timed sequential therapy with cytosine arabinoside and" exact="mitoxantrone" post="for adults with newly diagnosed, poor-risk acute myelogenous leukemia."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6912104\results\search\drugs\results.xml">
   <result pre="2 mM l-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 mg/ml" exact="streptomycin" post="(Gibco, Invitrogen) (Complete DC medium) and were supplemented with"/>
   <result pre="cells, supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml" exact="streptomycin" post="(Gibco, Invitrogen). Primary normal human bronchial epithelial (NHBE) cells"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6912272\results\search\drugs\results.xml">
   <result pre="figure legends, before quantification of cell death. For intrinsic apoptosis," exact="etoposide" post="at 10 µM or blasticidin at 5 µg.mL−1 (InvivoGen,"/>
   <result pre="(Thermofisher, Les Ulis, France) and selected for 5 days in" exact="puromycin" post="at 1 µg.mL−1. The production of A549 cells transiently"/>
   <result pre="which causes chromosome breaks during DNA replication. Overnight treatment with" exact="etoposide" post="(16–18 h) resulted in a percentage of cells with"/>
   <result pre="modest, apoptosis produced in A549 cells after 16 h of" exact="etoposide" post="treatment was significantly reduced in the case where ZIKV"/>
   <result pre="strains, we looked at the effect of apoptosis induction with" exact="etoposide" post="after infection with the epidemic clinical isolate PF13 (ZIKV-PF13)"/>
   <result pre="self-replicating RNA encoding the viral NS proteins from MR766-NIID, a" exact="puromycin" post="resistance gene to facilitate selection and GFP as a"/>
   <result pre="transfected with a plasmid encoding a GFP reporter gene and" exact="puromycin" post="resistance without any viral material was used as a"/>
   <result pre="CT; Figure 6). Apoptosis was induced either with TNFα/CHX, with" exact="etoposide" post="or with blasticidin. We monitored apoptosis and in particular"/>
   <result pre="post addition of TNFα/CHX or 16 h post addition of" exact="etoposide" post="or blasticidin. We compared the values related to caspase"/>
   <result pre="the case of the cell control, selected for GFP and" exact="puromycin" post="resistance (HEK CT) as well as in untransfected HEK-293"/>
   <result pre="(data not shown). It can be concluded that resistance to" exact="puromycin" post="or the presence of a GFP encoding gene were"/>
   <result pre="Apoptosis was induced 48 h after amplicon transfection either by" exact="etoposide" post="treatment (Figure 7B) or by DNA damage through exposure"/>
   <result pre="as by an intrinsic signal (provided by the action of" exact="etoposide" post="or blasticidin). Resistance to these induction modes has also"/>
   <result pre="at MOI of 1 for 8 h and treated with" exact="etoposide" post="2 h before infection (2 hbi) or 2 h"/>
   <result pre="at MOI of 1 for 8 h and treated with" exact="etoposide" post="for 16 h, 2 hpi. The percentage of A549"/>
   <result pre="with TNFα and CHX for 6 h, or treated with" exact="etoposide" post="10 µM or blasticidin 25 µg/mL−1 for 16 h"/>
   <result pre="At 48 h after transfection A549 cells were treated with" exact="etoposide" post="for 16 h (B) or UV at 400 mJ"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6912530\results\search\drugs\results.xml">
   <result pre="replication of many viruses through inhibition of pH-dependent steps. Recently," exact="chloroquine" post="was shown to inhibit Zika virus infection in different"/>
   <result pre="cells infected with BR15 or BR15E-MUT with 100 µM of" exact="chloroquine" post="1 hpi for 2 h and then cells were"/>
   <result pre="30 hpi by RT-qPCR. BR15E-MUT fusion was significantly restricted by" exact="chloroquine" post="treatment compared to that of BR15 (Figure 4). These"/>
   <result pre="our observations. One interesting finding from this study is that" exact="chloroquine" post="treatment results in less BR15E-MUT entries than it does"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6913311\results\search\drugs\results.xml">
   <result pre="antipyretic in children [5] and to be more effective than" exact="oseltamivir" post="in children younger than 5 years of age [6]."/>
   <result pre="penicillin G (100 units/ml, Meiji Seika Pharma, Tokyo, Japan), and" exact="streptomycin" post="(100 µg/ml, Meiji Seika Pharma). Human influenza virus strain A/Udorn/72"/>
   <result pre="2.5 or 3 mg/ml in DMEM supplemented with penicillin G and" exact="streptomycin" post="at 50°C for 1 h, clarified by low-speed centrifugation following"/>
   <result pre="of maoto in an influenza season where reduced effectiveness of" exact="oseltamivir" post="was observed—a clinical, non-randomized study in childrenForschende Komplementärmedizin/Research in"/>
   <result pre="of kakkonto, Japanese traditional (kampo) medicine, on brain penetration of" exact="oseltamivir" post="carboxylate in mice with reduced blood-brain barrier functionEvidence-Based Complementary"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6913923\results\search\drugs\results.xml">
   <result pre="by fluorescence spectroscopy, which was used to monitor the intrinsic" exact="tryptophan" post="fluorescence in the buffer containing 8M urea and after"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6919333\results\search\drugs\results.xml">
   <result pre="worse prognosis. Although treatment is predominantly supportive, early use of" exact="cidofovir" post="may improve outcomes. Conclusions These rare cases highlight that"/>
   <result pre="exacerbation precipitated by LRTI was made. Antimicrobial treatment commenced included" exact="oseltamivir" post="(due to presentation during peak of influenza season and"/>
   <result pre="factors for viral pneumonitis including chronic lung disease and obesity)," exact="benzylpenicillin" post="and clarithromycin. Respiratory distress was treated with oxygen therapy,"/>
   <result pre="Dependency Unit (HDU, Level-2 Care) for respiratory support. Aminophylline and" exact="salbutamol" post="infusions and CPAP were instigated but she deteriorated and"/>
   <result pre="2 respiratory failure. In an attempt to improve ventilation, inhaled" exact="nitric oxide" post="was commenced and the patient turned into the prone"/>
   <result pre="polymerase chain reaction (PCR) test (Table 1) and twice weekly" exact="cidofovir" post="(with a loading dose one week after the initial"/>
   <result pre="left middle-zone consolidation. He was diagnosed with community-acquired pneumonia and" exact="benzylpenicillin" post="and clarithromycin were started. By day 2, he had"/>
   <result pre="consolidation. He was diagnosed with community-acquired pneumonia and benzylpenicillin and" exact="clarithromycin" post="were started. By day 2, he had deteriorated with"/>
   <result pre="was no improvement and antibiotics were empirically changed to meropenem," exact="doxycycline" post="and linezolid. By day 6, he required transfer to"/>
   <result pre="were strong positives (Table 1) and a single dose of" exact="cidofovir" post="was given. No other bacterial or viral pathogens were"/>
   <result pre="worse prognosis. Although treatment is predominantly supportive, early use of" exact="cidofovir" post="may improve outcomes. These two rare cases highlight that"/>
   <result pre="7 revisitedRespiratory medicine; Oxford10711Nov 201318101813 9.KimS.J.KimK.ParkS.B.HongD.J.JhunB.W.Outcomes of early administration of" exact="cidofovir" post="in non-immunocompromised patients with severe adenovirus pneumoniaPLoS One1042015 Apr"/>
   <result pre="Sep 2527681877 20.LeeM.KimS.KwonO.J.Treatment of adenoviral acute respiratory distress syndrome using" exact="cidofovir" post="with extracorporeal membrane oxygenationJ Intensive Care Med3232017 Mar231238Epub 2016"/>
   <result pre="Med3232017 Mar231238Epub 2016 Nov 3027903788 21.KimS.J.KimK.ParkS.B.Outcomes of early administration of" exact="cidofovir" post="in non-immunocompromised patients with severe adenovirus pneumoniaPLoS One1042015 Apr"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6920831\results\search\drugs\results.xml">
   <result pre="ceramides of specific chain length in multiple sclerosis patients, unlike" exact="fingolimod" post="or natalizumabFront. Pharmacol.2016741210.3389/fphar.2016.0041227857690 106.O’SheaD.HoganA.E.Dysregulation of natural killer cells in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6923871\results\search\drugs\results.xml">
   <result pre="PAN Biotech), 5 mM L-glutamine (Q; Life Technologies), 50 U/mL penicillin, and 50 μg/mL" exact="streptomycin" post="(PS; Life Technologies). Plasmids and transfection Plasmids encoding the"/>
   <result pre="described [9]. The transfection was performed in 50 μL Opti-MEM without" exact="phenol" post="red (Life Technologies) using TranSIT (Mirus) according to the"/>
   <result pre="of cells with cytoskeleton-modulating drugs Cells were treated with 15 μM" exact="nocodazole" post="(Sigma), 0.3 μM cytochalasin D (Sigma), or 0.15% dimethyl sulfoxide"/>
   <result pre="with 15 μM nocodazole (Sigma), 0.3 μM cytochalasin D (Sigma), or 0.15%" exact="dimethyl sulfoxide" post="(DMSO, Sigma), following previous publication [9]. The chemicals were"/>
   <result pre="MARV NCLSs transport In MARV-infected cells, the microtubule depolymerizing drug" exact="nocodazole" post="does not alter the movement of nucleocapsids, whereas the"/>
   <result pre="of nucleocapsid transport in MARV-infected cells treated with DMSO and" exact="nocodazole" post="was 379 ± 61 nm/s and 334 ± 55 nm/s, respectively [9]. A reduction in"/>
   <result pre="VP30-GFP. The cells were treated at 15 h p.t. with 0.15 μM" exact="nocodazole" post="for 3 h. Time-lapse images of cells were recorded for"/>
   <result pre="NCLS Nucleocapsid-like structure NP Nucleoprotein p.t post-transfection PS Penicillin and" exact="streptomycin" post="Q L-glutamine SD Standard deviation VLP Virus-like particle Publisher’s"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6925274\results\search\drugs\results.xml">
   <result pre="procedures All animal procedures were performed under anesthesia with either" exact="ketamine" post="(10 mg/kg intramuscularly or intravenously), Dormitor (0.015 mg/kg intramuscularly), or under"/>
   <result pre="10 m m Hepes buffer (Quality Biological, Gaithersburg, MD), 2 m m" exact="l-glutamine" post="(Quality Biological), 100 μg/ml penicillin/streptomycin (Quality Biological) and kept on"/>
   <result pre="American Academy of Pediatrics: Policy statements–Modified recommendations for use of" exact="palivizumab" post="for prevention of respiratory syncytial virus infectionsPediatrics20091241694170110.1542/peds.2009-234519736258 10.FulginitiVAet al.Respiratory"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6927920\results\search\drugs\results.xml">
   <result pre="Six-to-8-week-old C57BL/6 STAT2–/– mice were anesthetized by inhalation of 4%" exact="isoflurane" post="and inoculated i.n. at the indicated amount of viruses."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6936527\results\search\drugs\results.xml">
   <result pre="J. Virol.86, 2864–2868 (2012).22190717 48OhW. S.et al., Plasma exchange and" exact="ribavirin" post="for rapidly progressive severe fever with thrombocytopenia syndrome. Int."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6936826\results\search\drugs\results.xml">
   <result pre="2013. Eighty-eight of those diagnosed reported injection use of extended-release" exact="oxymorphone" post="which may be crushed, dissolved, and cooked [44, 45]."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6937093\results\search\drugs\results.xml">
   <result pre="been vastly underestimated. Neuraminidase inhibitors Neuraminidase inhibitors (NAIs) such as" exact="oseltamivir" post="(Tamiflu) are recommended by Public Health England (PHE) and"/>
   <result pre="data. Lancet Respir Med2014;2:395–404. 10.1016/S2213-2600(14)70041-424815805 17KatzenJ, KohnR, HoukJL, et al.Early" exact="oseltamivir" post="after hospital admission is associated with shortened hospitalization: a"/>
   <result pre="admission is associated with shortened hospitalization: a 5-year analysis of" exact="oseltamivir" post="timing and clinical outcomes. Clin Infect Dis2019;69:52–8. 10.1093/cid/ciy86030304487 18collab:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6940900\results\search\drugs\results.xml">
   <result pre="respectively, which showed that NC-5 had a great advantage over" exact="oseltamivir" post="in drug-resistant virus infections. The 50% cytotoxic concentration (CC50)"/>
   <result pre="and Glu119 [5]. Benefitting from alkylation and guanidylation of the" exact="oseltamivir" post="C-5 amino acid and the same transformations at position"/>
   <result pre="reported to show potent antiviral activity [15]. The analogs of" exact="oseltamivir" post="and zanamivir that possess a triazole substituent had been"/>
   <result pre="show potent antiviral activity [15]. The analogs of oseltamivir and" exact="zanamivir" post="that possess a triazole substituent had been reported to"/>
   <result pre="than 480 μM. For oseltamivir-resistant strains, the inhibition rates of" exact="oseltamivir" post="at 1 nM were less than 2% compared with"/>
   <result pre="considerable protective effect. H1N1, H1N1-H275Y and H3N2 were tested with" exact="oseltamivir" post="carboxylate (OC) as a control. NC-5 (10–160 μM) showed"/>
   <result pre="microscopic observation, which detected a far lower CPE than the" exact="dimethyl sulfoxide" post="(DMSO) control and the OC-treated cells (Figure 3E). NC-5"/>
   <result pre="subsequent studies. Compared to the two widely used anti-influenza drugs," exact="zanamivir" post="and oseltamivir, BANA-206 and NC-5 are achiral molecules exhibiting"/>
   <result pre="Chinese Academy of Sciences. 4.2. Compounds Oseltamivir phosphate (OS) and" exact="oseltamivir" post="carboxylate (OC) were purchased from MedChem Express (Shanghai, China)."/>
   <result pre="later, NC-5 (50 mg/kg/d, 75 mg/kg/d and 100 mg/kg/d) or" exact="oseltamivir" post="phosphate (OS) (100 mg/kg/d) was given twice daily for"/>
   <result pre="NC-5 (10 μM, 40 μM and 80 μM), DMSO and" exact="ribavirin" post="(RBV) (40 μM). The cell lysates were collected after"/>
   <result pre="DMEM Dulbecco’s modified Eagle’s medium CHO-K1 Chinese hamster ovary OS" exact="oseltamivir" post="phosphate OC oseltamivir carboxylate RBV ribavirin CPE cytopathic effect"/>
   <result pre="Eagle’s medium CHO-K1 Chinese hamster ovary OS oseltamivir phosphate OC" exact="oseltamivir" post="carboxylate RBV ribavirin CPE cytopathic effect EC50 50% effective"/>
   <result pre="Chinese hamster ovary OS oseltamivir phosphate OC oseltamivir carboxylate RBV" exact="ribavirin" post="CPE cytopathic effect EC50 50% effective concentrations CC50 50%"/>
   <result pre="acylthiourea derivatives possessing broad-spectrum antiviral activityBioorg. Med. Chem. Lett2012224263427210.1016/j.bmcl.2012.05.03522664128 13.TarbetE.B.HamiltonS.VollmerA.H.LuttickA.NgW.C.PryorM.HurstB.L.CrawfordS.SmeeD.F.TuckerS.P.A" exact="zanamivir" post="dimer with prophylactic and enhanced therapeutic activity against influenza"/>
   <result pre="experiments, *p &amp;lt;0.05, **p &amp;lt;0.01, ***p &amp;lt;0.001, compared with the" exact="dimethyl sulfoxide" post="(DMSO) control. Figure 3 Inhibitory effect of NC-5 on"/>
   <result pre="and ten mice in each group received placebo, NC-5 or" exact="oseltamivir" post="phosphate (OS) twice daily for 5 days. (A) Survival"/>
   <result pre="ten mice in each group received a placebo, NC-5 or" exact="oseltamivir" post="phosphate (OS) twice daily for 5 days. (A) Survival"/>
   <result pre="(CPE) reduction assays. a substituent group on the triazole. b" exact="oseltamivir" post="carboxylate. c not detected."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6941257\results\search\drugs\results.xml">
   <result pre="the concentration of 1.1 μM, could substantially decrease the amount of" exact="ampicillin" post="needed for the similar inhibition, as well as, prevented"/>
   <result pre="ineffective against biofilm formation in S. choleraesuis infections. Aptamer -" exact="ampicillin" post="conjugate could produce synergistic results against biofilms. Aptamer as"/>
   <result pre="synergistic results against biofilms. Aptamer as the antibiotic carrier, helped" exact="ampicillin" post="to penetrate into the biofilm and kill the bacteria"/>
   <result pre="by using DNA oligonucleotide as aptamer similar agent, that increased" exact="tetracycline" post="loading and sustained its release. The study was designed"/>
   <result pre="and tetracycline. This oligonucleotide could rise the partition coefficient of" exact="tetracycline" post="between hydrogels and drug loading solutions and also, it"/>
   <result pre="loading solutions and also, it could slow the release of" exact="tetracycline" post="from hydrogels to increase bacterial inhibition [67]. Aptamer conjugates"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6955252\results\search\drugs\results.xml">
   <result pre="It has been reported that stimulation of α2-adrenergic receptors by" exact="clonidine" post="inhibits IAV replication (22), and treatment of mice with"/>
   <result pre="(22), and treatment of mice with the angiotensin II inhibitor" exact="losartan" post="alleviates lung edema and improves lung histopathology, although the"/>
   <result pre="(H5N1) virus titer at 24 h p.i. compared with that in" exact="dimethyl sulfoxide" post="(DMSO)-treated cells, whereas a slight inhibitory effect on virus"/>
   <result pre="10% FBS, respectively. All media contained 100 U/ml penicillin and 100 μg/ml" exact="streptomycin" post="(Life Technologies). Venus-expressing reporter influenza viruses, H1N1 NA-Venus, H5N1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6958409\results\search\drugs\results.xml">
   <result pre="the clinic are Matrix 2 (M2) ion channel inhibitors, (e.g.," exact="amantadine" post="and rimantadine) and neuraminidase (NA) inhibitors (e.g., oseltamivir and"/>
   <result pre="inhibitors, (e.g., amantadine and rimantadine) and neuraminidase (NA) inhibitors (e.g.," exact="oseltamivir" post="and zanamivir) [6]. The emergence of resistant virus strains"/>
   <result pre="to be functional and could be inhibited upon addition of" exact="oseltamivir" post="and zanamivr [132], suggesting that the yeast-based system is"/>
   <result pre="M2 and compared the efficacy of the novel compounds to" exact="amantadine" post="which led to new lead compounds against M2 [134,135]."/>
   <result pre="found to have a more severe phenotype than females. Importantly," exact="amantadine" post="was shown to rescue the M2 phenotype, suggesting Drosophila"/>
   <result pre="intracellular reactive oxygen species (ROS) and had increased expression of" exact="nicotinamide" post="adenine dinucleotide phosphate oxidases (Nox) [256]. One particular Nox"/>
   <result pre="same patients. Using TVB024 prophylactically, the combination of TVB024 and" exact="oseltamivir" post="reduced viral shedding and this was more effective than"/>
   <result pre="oseltamivir reduced viral shedding and this was more effective than" exact="oseltamivir" post="alone in inhibiting epithelial infection. In addition, infected NHBE"/>
   <result pre="virus NS1 and Postsynaptic density protein-95 (PSD-95), and inhibition of" exact="nitric oxide" post="productionVirol. J.2011829810.1186/1743-422X-8-29821668967 152.WolffT.O’NeillR.E.PaleseP.Interaction cloning of NS1-I, a human protein"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6958466\results\search\drugs\results.xml">
   <result pre="The structure of ZIKV MTase with the S-adenosyl-L-methionine (SAM) analog," exact="sinefungin" post="was recently elucidated. In the structural elucidation, Hercik et"/>
   <result pre="Hercik et al. proposed that designing of an inhibitor connecting" exact="sinefungin" post="with a Cap analog through a linker could provide"/>
   <result pre="ZIKV (EC50 = 142.9 mg/mL) [126]. However, poor inhibition of" exact="ribavirin" post="as shown in the above virus-induced CPE study indicates"/>
   <result pre="further development particularly as antivirals against ZIKV [127]. BCX4430 an" exact="adenosine" post="nucleoside analog has shown EC50 values in the low"/>
   <result pre="safety and better efficacy evaluations. Another RdRp inhibitor, NITD008, an" exact="adenosine" post="nucleoside analog, has also exhibited antiviral activity against ZIKV"/>
   <result pre="identify nine that could inhibit ZIKV replication. Among these inhibitors," exact="seliciclib" post="(a purine analog, also known as roscovitine) and RGB-286147"/>
   <result pre="the hypothesis by demonstrating anti-ZIKV activities of compounds such as" exact="warfarin" post="and a few similar structural analogues identified using in"/>
   <result pre="based on the measurement of intracellular viral RNA [95]. Incidentally," exact="niclosamide" post="is an FDA-approved drug, mainly used in the treatment"/>
   <result pre="unfolded protein response and autophagyFront. Microbiol.201451710.3389/fmicb.2014.0026624478763 140.KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and" exact="gemcitabine" post="inhibit Zika virus infection in vitro and differentially affect"/>
   <result pre="congenital microcephaly in miceEBioMedicine20172418919410.1016/j.ebiom.2017.09.03429033372 156.ShiryaevS.A.MesciP.PintoA.FernandesI.SheetsN.ShrestaS.FarhyC.HuangC.-T.StronginA.Y.MuotriA.R.et al.Repurposing of the anti-malaria drug" exact="chloroquine" post="for Zika virus treatment and prophylaxisSci. Rep.201771577110.1038/s41598-017-15467-629150641 157.HanY.MespledeT.XuH.QuanY.WainbergM.A.The antimalarial"/>
   <result pre="for Zika virus treatment and prophylaxisSci. Rep.201771577110.1038/s41598-017-15467-629150641 157.HanY.MespledeT.XuH.QuanY.WainbergM.A.The antimalarial drug" exact="amodiaquine" post="possesses anti-ZIKA virus activitiesJ. Med. Virol.20189079680210.1002/jmv.2503129315671 158.ZhouT.TanL.CederquistG.Y.FanY.HartleyB.J.MukherjeeS.TomishimaM.BrennandK.J.ZhangQ.SchwartzR.E.et al.High-content screening"/>
   <result pre="in vitro plaque assay [104] NITD008 A type of nucleoside" exact="adenosine" post="analog [105] Warfarin and a few similar structural analogues"/>
   <result pre="[93,95] Lovastatin and Mevastatin HMG-CoA reductase inhibitor [112] BCX4430 An" exact="adenosine" post="nucleoside analog, functions as a selective inhibitor of viral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963298\results\search\drugs\results.xml">
   <result pre="care may include nutritional support, administration of intravenous fluids, and" exact="acetaminophen" post="for pain and fever. Patients with severe disease require"/>
   <result pre="Res20139824224710.1016/j.antiviral.2013.01.01123470860 57.de FreitasC.S.HigaL.M.SacramentoC.Q.FerreiraA.C.ReisP.A.DelvecchioR.MonteiroF.L.Barbosa-LimaG.James WestgarthH.VieiraY.R.et al.Yellow fever virus is susceptible to" exact="sofosbuvir" post="both in vitro and in vivoPLoS Negl. Trop. Dis.201913e000707210.1371/journal.pntd.000707230699122"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963304\results\search\drugs\results.xml">
   <result pre="noncytotoxic concentrations [14]. In addition, it has been reported that" exact="lithium" post="chloride (LiCl) and diammonium glycyrrhizinate (DG) have good inhibitory"/>
   <result pre="(CAS 6902-91-6) was purchased from Weikeqi (China) and dissolved in" exact="dimethyl sulfoxide" post="(DMSO) at 20 mM. Lithium chloride (LiCl) (Sigma, St."/>
   <result pre="useful for clinical applications [31,32]. In particular, the germacrone and" exact="oseltamivir" post="combination has a synergistic effect on the inhibition of"/>
   <result pre="MatterACS Appl. Mater. Interfaces20157215712157910.1021/acsami.5b0687626370151 15.SuiX.YinJ.RenX.Antiviral effect of diammonium glycyrrhizinate and" exact="lithium" post="chloride on cell infection by pseudorabies herpesvirusAntivir. Res.20108534635310.1016/j.antiviral.2009.10.01419879899 16.FengJ.BaiX.CuiT.ZhouH.ChenY.XieJ.ShiQ.WangH.ZhangG.In"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963661\results\search\drugs\results.xml">
   <result pre="IFN and pro-inflammatory cytokine production, Toll-like receptor (TLR) expression, and" exact="nitric oxide" post="radicals, whilst increasing IL-10 expression. This consequently led to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963678\results\search\drugs\results.xml">
   <result pre="neuroinvasive disease. In 14 patients with acute WNV meningoencephalitis, intravenous" exact="dexamethasone" post="injection was suggested to play a critical role in"/>
   <result pre="facial paralysis within 24 h of treatment with high-dose intravenous" exact="methylprednisolone" post="[25]. A recent report of a ‘Lazarus-like effect’ of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963926\results\search\drugs\results.xml">
   <result pre="vaccines: The future of TIV and QIVCurr. Opin. Virol.20172310210610.1016/j.coviro.2017.04.00528505524 45.JacksonR.J.CooperK.L.TappendenP.ReesA.SimpsonE.L.ReadR.C.NicholsonK.G.Oseltamivir," exact="zanamivir" post="and amantadine in the prevention of influenza: A systematic"/>
   <result pre="future of TIV and QIVCurr. Opin. Virol.20172310210610.1016/j.coviro.2017.04.00528505524 45.JacksonR.J.CooperK.L.TappendenP.ReesA.SimpsonE.L.ReadR.C.NicholsonK.G.Oseltamivir, zanamivir and" exact="amantadine" post="in the prevention of influenza: A systematic reviewJ. Infect.201162142510.1016/j.jinf.2010.10.00320950645"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6972593\results\search\drugs\results.xml">
   <result pre="Virus infection models and treatment regimens Mice were anaesthetized by" exact="isoflurane" post="inhalation (2–5% isoflurane/95% oxygen air mixture) and then treated"/>
   <result pre="IAV as well as by activation of the TLR7 with" exact="imiquimod" post="in isolated macrophages and in lung tissue in vivo.9"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6977312\results\search\drugs\results.xml">
   <result pre="evaluated the feasibility of a randomized, placebo-controlled trial using intravenous" exact="ribavirin" post="in patients with suspected severe RVF, but no official"/>
   <result pre="Pathogens Laboratory Network in 2016, it was briefly mentioned that" exact="ribavirin" post="was used without efficacy in Saudi Arabia [101]. Evidence"/>
   <result pre="was used without efficacy in Saudi Arabia [101]. Evidence suggests" exact="ribavirin" post="efficacy in animal models [102, 103], but it failed"/>
   <result pre="case reports of encephalitis, the use of amantadine, rifampicin, and" exact="dexamethasone" post="[72], doubled prednisone doses with a stop in immunosuppressive"/>
   <result pre="encephalitis, the use of amantadine, rifampicin, and dexamethasone [72], doubled" exact="prednisone" post="doses with a stop in immunosuppressive drugs [74], and"/>
   <result pre="prednisone doses with a stop in immunosuppressive drugs [74], and" exact="phenytoin" post="[70] were reported but not evaluated precisely. Early renal"/>
   <result pre="l’homme. https://studylibfr.com/doc/1012718/fièvre-de-la-vallée-du-rift-en-afrique–aspects-cliniques. Accessed 30 June 2019. 102.KendeMAlvingCRRillWLSwartzGMCanonicoPGEnhanced efficacy of liposome-encapsulated" exact="ribavirin" post="against Rift Valley fever virus infection in miceAntimicrob Agents"/>
   <result pre="the literature and proposed guidelines for the use of oral" exact="ribavirin" post="as postexposure prophylaxis for Lassa feverClin Infect Dis2010511435144110.1086/65731521058912 106.IslamMKStrandMSaleebMSvenssonRBaranczewskiPArturssonPet"/>
   <result pre="fever virus infection and reduces delayed-onset neurologic disease observed with" exact="ribavirin" post="treatmentAntiviral Res2014104849210.1016/j.antiviral.2014.01.01624486952 108.SmeeDFJungK-HWestoverJGowenBB2′-Fluoro-2′-deoxycytidine is a broad-spectrum inhibitor of bunyaviruses"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6981203\results\search\drugs\results.xml">
   <result pre="(Biolegend). Mice were sacrificed post-infection by a fatal dose of" exact="pentobarbital" post="injected intraperitonially (i.p.). Antibody mediated neutrophil depletion Two regimes"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6983437\results\search\drugs\results.xml">
   <result pre="young children and elderly people.(2,3) The M2 ion channel inhibitors" exact="amantadine" post="and rimantadine and neuraminidase inhibitors zanamivir and oseltamivir have"/>
   <result pre="and elderly people.(2,3) The M2 ion channel inhibitors amantadine and" exact="rimantadine" post="and neuraminidase inhibitors zanamivir and oseltamivir have been used"/>
   <result pre="M2 ion channel inhibitors amantadine and rimantadine and neuraminidase inhibitors" exact="zanamivir" post="and oseltamivir have been used to treat influenza virus"/>
   <result pre="channel inhibitors amantadine and rimantadine and neuraminidase inhibitors zanamivir and" exact="oseltamivir" post="have been used to treat influenza virus infections. Recently,"/>
   <result pre="that daidzein enhances the enzymatic activity of 5-LOX. Effect of" exact="zileuton" post="on influenza virus replication in daidzein added virus-infected cells"/>
   <result pre="inhibition of virus replication was decreased in the presence of" exact="zileuton" post="from 72% [flu: flu + daidzein, inhibition rate ="/>
   <result pre="106 (%)] (Fig. 4A). The virus titer was increased by" exact="zileuton" post="to 212% [flu + daidzein: flu + daidzein +"/>
   <result pre="hypothesized that daidzein affected 5-LOX-mediated enzymatic oxidation of AA, as" exact="zileuton" post="inhibited daidzein-induced antiviral activity. We attempted to knockdown endogenous"/>
   <result pre="activity of daidzein (Fig. 4A). However, the reduction effect of" exact="zileuton" post="on daidzein-induced 5-HETE production was not significant (Fig. 4B)."/>
   <result pre="This indicates that even a slight reduction in 5-HETE by" exact="zileuton" post="addition can affect viral replication. Additionally, 5-HETE is produced"/>
   <result pre="5-HETE generated by ROS relative to the total 5-HETE level," exact="zileuton" post="did not effectively suppress 5-HETE production because zileuton did"/>
   <result pre="5-HETE level, zileuton did not effectively suppress 5-HETE production because" exact="zileuton" post="did not suppress ROS-mediated 5-HETE generation. This may be"/>
   <result pre="did not suppress ROS-mediated 5-HETE generation. This may be because" exact="zileuton" post="could not significantly reduce 5-HETE generation without daidzein administration"/>
   <result pre="5BloomJD, GongLI, BaltimoreDPermissive secondary mutations enable the evolution of influenza" exact="oseltamivir" post="resistance. Science2010; 328: 1272–1275.20522774 6FurutaY, TakahashiK, FukudaY, et al.In"/>
   <result pre="Food Agric2018; 98: 1899–1905.28902408 9ChristenS, PeterhansE, StockerRAntioxidant activities of some" exact="tryptophan" post="metabolites: possible implication for inflammatory diseases. Proc Natl Acad"/>
   <result pre="IjiriS, et al.Pathogenesis of influenza virus-induced pneumonia: involvement of both" exact="nitric oxide" post="and oxygen radicals. Proc Natl Acad Sci U S"/>
   <result pre="Proteomics2010; 10: 976–986.20049867 23HafezHS, GhareebDA, SalehSR, et al.Neuroprotective effect of" exact="ipriflavone" post="against scopolamine-induced memory impairment in rats. Psychopharmacology (Berl)2017; 234:"/>
   <result pre="novel role for α-tocopherol transfer protein (α-TTP) in protecting against" exact="chloroquine" post="toxicity. J Biol Chem2012; 287: 2926–2934.22147702 30SteinhilberD, FischerAS, MetznerJ,"/>
   <result pre="at 24 h post-infection by focus-forming assays. (A) Effect of" exact="zileuton" post="on the titer of influenza virus. (B) Effect of"/>
   <result pre="zileuton on the titer of influenza virus. (B) Effect of" exact="zileuton" post="on 5-HETE production. (C) Effect of 5-LOX siRNA on"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6989424\results\search\drugs\results.xml">
   <result pre="The average purity was &amp;gt;85%. Lyophilized peptides were dissolved in" exact="dimethyl sulfoxide" post="and diluted in AIM-V medium (23). A total of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6991954\results\search\drugs\results.xml">
   <result pre="More recent antibodies have been developed as subcutaneous injections, and" exact="adalimumab" post="has taken over as the market leader, with an"/>
   <result pre="Phase II clinical studies [15]—is 100 times more potent than" exact="palivizumab" post="in vitro. It is being developed as a single"/>
   <result pre="surface, escaping degradation [24, 25]. This approach was followed for" exact="bevacizumab" post="and cetuximab, by mutating Met428 to Leu and Asn434"/>
   <result pre="not possible or desirable. In the case of inhalational anthrax," exact="raxibacumab" post="has been approved using the FDA &quot;Animal Rule�? [33]."/>
   <result pre="to start to build one, with the recent characterization of" exact="praziquantel" post="for such use in murine models and in pediatrics."/>
   <result pre="consisting of a full treatment course of 3 days of" exact="amodiaquine" post="and 1 dose of sulfadoxine/pyrimethamine. It is given monthly"/>
   <result pre="67CoulibalyJT, PanicG, SilueKD, KovacJ, HattendorfJ, KeiserJ. Efficacy and safety of" exact="praziquantel" post="in preschool-aged and school-aged children infected with Schistosoma mansoni:"/>
   <result pre="VargasM, ReimersN, HaasH, SpangenbergT. Evaluation of the pharmacokinetic-pharmacodynamic relationship of" exact="praziquantel" post="in the Schistosoma mansoni mouse model. PLoS Negl Trop"/>
   <result pre="2017;11(9):e000594210.1371/journal.pntd.000594228934207 70BonatePL, WangT, PassierP, BagchusW, BurtH, LupfertC, et al.Extrapolation of" exact="praziquantel" post="pharmacokinetics to a pediatric population: a cautionary tale. Journal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6992227\results\search\drugs\results.xml">
   <result pre="GP protein is encoded by the addition of a single" exact="adenosine" post="residue at the editing site, which occurs in about"/>
   <result pre="about 5% of the GP gene-specific transcripts, addition of two" exact="adenosine" post="residues generates transcripts encoding the non-structural small secreted GP"/>
   <result pre="Fetal Calf Serum (FCS) (Eurobio, France), penicillin (100 IU/ml) and" exact="streptomycin" post="(100 μg/ml) and supplemented with hypoxantine (1×10−4 M), aminopterin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6993835\results\search\drugs\results.xml">
   <result pre="of LGI1. Anti-GABAb R antibodies block the inhibitory effects of" exact="baclofen" post="on the spontaneous firing of cultured neurons and influence"/>
   <result pre="2. Convulsions are best managed with intravenous anticonvulsants such as" exact="phenytoin" post="or valproate which do not depress the sensorium. Tube"/>
   <result pre="are best managed with intravenous anticonvulsants such as phenytoin or" exact="valproate" post="which do not depress the sensorium. Tube feeding may"/>
   <result pre="to 1.0 mg/kg every 4 to 6 hours) or intravenous" exact="furosemide" post="may be needed. Hypertonic saline (3%) in a dose"/>
   <result pre="of viral infection with steroids. A study that evaluated high-dose" exact="dexamethasone" post="in JE found no benefit of steroid therapy 55."/>
   <result pre="59. Acyclovir is also recommended for varicella zoster encephalitis, and" exact="ganciclovir" post="is an alternative drug. A combination of ganciclovir and"/>
   <result pre="encephalitis, and ganciclovir is an alternative drug. A combination of" exact="ganciclovir" post="and foscarnet is recommended for cytomegaloviral encephalitis 59. Pleconaril"/>
   <result pre="influenza (H1N1) encephalitis/encephalopathy 59. Trials with interferon alpha and nasogastric" exact="ribavirin" post="in JE in children have revealed no benefit 61,"/>
   <result pre="JE in children have revealed no benefit 61, 62. The" exact="tetracycline" post="drug minocycline is a known neuroprotective agent with antiviral"/>
   <result pre="children have revealed no benefit 61, 62. The tetracycline drug" exact="minocycline" post="is a known neuroprotective agent with antiviral properties and"/>
   <result pre="properties and excellent penetration into CSF. A trial of nasogastric" exact="minocycline" post="in AES in Lucknow revealed modest benefit in terms"/>
   <result pre="at 3 months from onset and neurologic sequelae 63. Intravenous" exact="azithromycin" post="or oral minocycline/doxycycline is currently recommended for rickettsial meningoencephalitis"/>
   <result pre="for rickettsial meningoencephalitis 64.Treatment of AIE is immunosuppression through high-dose" exact="methylprednisolone" post="pulse therapy, intravenous immunoglobulin, plasmapheresis, rituximab, and azathioprine 31."/>
   <result pre="through high-dose methylprednisolone pulse therapy, intravenous immunoglobulin, plasmapheresis, rituximab, and" exact="azathioprine" post="31. References 1ProberCGSrinivasNS: Viral meningoencephalitis.In: Nelson Textbook of Pediatrics,"/>
   <result pre="Intracranial Pressure.J Neurocrit Care.2016;9(2):105–12. 10.18700/jnc.160101 55HokeCHJrVaughnDWNisalakAet al.: Effect of high-dose" exact="dexamethasone" post="on the outcome of acute encephalitis due to Japanese"/>
   <result pre="placebo-controlled trial.Lancet.2003;361(9360):821–6. 10.1016/s0140-6736(03)12709-212642049 62KumarRTripathiPBaranwalMet al.: Randomized, controlled trial of oral" exact="ribavirin" post="for Japanese encephalitis in children in Uttar Pradesh, India.Clin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6994196\results\search\drugs\results.xml">
   <result pre="ewes that had delivered healthy lambs before, were treated with" exact="progesterone" post="sponges to synchronise pregnancies. After removal of the sponges,"/>
   <result pre="foetuses were euthanized by intravenous administration of 50 mg/kg sodium" exact="pentobarbital" post="(Euthasol, ASTfarma) and subsequent exsanguination. Foetuses were exsanguinated by"/>
   <result pre="foetal mortality before foetuses could be infected. During gestation, the" exact="progesterone" post="hormone keeps the uterus and myometrium in a quiescent"/>
   <result pre="parturition [24]. During the first trimester of gestation in sheep," exact="progesterone" post="is produced by the corpus luteum which resides in"/>
   <result pre="the developing placenta becomes an additional source of progesterone. Placental" exact="progesterone" post="is produced by binucleate trophoblasts that migrate to the"/>
   <result pre="cells. At about 90 days of pregnancy, half of the" exact="progesterone" post="in the pregnant ewe is produced by the corpus"/>
   <result pre="of these cells likely results in a drop of systemic" exact="progesterone" post="levels. In addition, virus-induced necrosis of placental cells leads"/>
   <result pre="corpus luteum in regression, resulting in a further drop in" exact="progesterone" post="levels. In the absence of the inhibitory effect of"/>
   <result pre="24SoloffMS, JengYJ, IzbanMG, SinhaM, LuxonBA, et al. (2011) Effects of" exact="progesterone" post="treatment on expression of genes involved in uterine quiescence."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6995028\results\search\drugs\results.xml">
   <result pre="about 1 d in otherwise healthy adults (5, 6). Although" exact="oseltamivir" post="resistance among circulating strains has generally been low since"/>
   <result pre="against oseltamivir- and adamantane-resistant strains. As combination therapy with both" exact="oseltamivir" post="and H84T could be a potential strategy to treat"/>
   <result pre="oseltamivir-susceptible strains, we sought to determine whether synergy exists between" exact="oseltamivir" post="and H84T. Treatment of MDCK cells infected with A/California/07/2009"/>
   <result pre="A/California/07/2009 (H1N1)pdm09, A/Perth/16/2009 (H3N2), A/Duck/MN/1525/1981 (H5N1), and B/Brisbane/60/2008 with both" exact="oseltamivir" post="and H84T resulted in a virus yield reduction that"/>
   <result pre="compared to either individual drug alone, identifying possible synergy between" exact="oseltamivir" post="and H84T for all four viruses tested (21) (SI"/>
   <result pre="analysis (MacSynergy II) (22) and found that the combination of" exact="oseltamivir" post="and H84T has minor but significant synergy against both"/>
   <result pre="h postchallenge all survived, as compared to ∼90% treated with" exact="oseltamivir" post="twice daily and &amp;lt;20% treated with PBS. Strikingly, 80%"/>
   <result pre="4, 24, 48, or 72 h postchallenge, or treatment with" exact="oseltamivir" post="(10 mg/kg) beginning 4 or 72 h postchallenge. (C)"/>
   <result pre="The finding that there is some synergy between H84T and" exact="oseltamivir" post="raises the possibility of combination therapy, which might be"/>
   <result pre="Fig. 2. Control groups included mice treated with 10 mg/kg/d" exact="oseltamivir" post="twice daily for 5 d beginning 4, 24, 48,"/>
   <result pre="4 d postinfection. A group of 10 mice was given" exact="oseltamivir" post="by oral gavage twice daily for 5 d with"/>
   <result pre="Antibody Production. Eight-week-old female BALB/c mice (Taconic) were anesthetized with" exact="isoflurane" post="then injected intraperitoneally with either 50 mg/kg V66D/H84T/A100D BanLec,"/>
   <result pre="Antiviral Res.96, 13–20 (2012).22809862 17LackenbyA.et al., Emergence of resistance to" exact="oseltamivir" post="among influenza A(H1N1) viruses in Europe. Euro Surveill.13, 8026"/>
   <result pre="C., ChanceD., NahmiasA. J., Effect of combinations of acyclovir with" exact="vidarabine" post="or its 5′-monophosphate on herpes simplex viruses in cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6995199\results\search\drugs\results.xml">
   <result pre="Cultilab, Brazil), 2.5 μg/mL amphotericin B, 500 U/mL penicillin (Cristalia), and 50 μg/mL" exact="streptomycin" post="(Schering-Plough, São Paulo, Brazil). YFV (vaccine strain 17DD), MAYV"/>
   <result pre="0.25 μg/mL amphotericin B, 100 U/mL penicillin 100 U/mL (Schering-Plough, Brazil), and 100 μg/mL" exact="streptomycin" post="at 37 °C in an atmosphere with 5% CO2 in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6995725\results\search\drugs\results.xml">
   <result pre="suspected her of having cryptogenic organizing pneumonia (COP) and administered" exact="prednisolone" post="20 mg daily. Her chest shadows gradually improved, and"/>
   <result pre="against HPIV were not measured. We then gradually tapered the" exact="prednisolone" post="and stopped it two months after hospital discharge. At"/>
   <result pre="are approved for the treatment of HPIV infections. Corticosteroids, generally" exact="dexamethasone" post="and budesonide, are associated with fewer clinic visits and"/>
   <result pre="and admissions for croup and the reduced use of nebulized" exact="epinephrine" post="(15). We initially misdiagnosed our patient in Case 2"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6996850\results\search\drugs\results.xml">
   <result pre="the controls whereas no significant change in the levels of" exact="progesterone" post="and HCG was observed. Titres of IgM and IgG"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7001263\results\search\drugs\results.xml">
   <result pre="male circumcision; setting up HIV care and treatment clinic and" exact="methadone" post="clinics [2]. It is unclear whether these preventive measures"/>
   <result pre="population PWID aged 18 years or older, not enrolled in a" exact="methadone" post="program, were eligible for inclusion into the study, while"/>
   <result pre="and viral hepatitis testing services and enrolment to antiretroviral and" exact="methadone" post="schemes, which have shown clear benefits [18, 19]. We"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7002134\results\search\drugs\results.xml">
   <result pre="(Gibco) supplemented with 10% FBS (Gibco), penicillin (100 U/ml), and" exact="streptomycin" post="(100 μg/ml) at 37°C in a humidified atmosphere with"/>
   <result pre="containing 10% FBS, 2 mM l-glutamine, penicillin (100 U/ml), and" exact="streptomycin" post="(100 μg/ml). One hour later, adherent MLFs were rinsed"/>
   <result pre="were allowed to be cultured for 3 days, selected by" exact="puromycin" post="(1 μg/ml) (Invivogen) and single-cell sorting. The resulting clones"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7002824\results\search\drugs\results.xml">
   <result pre="viral reservoir is resolved. To solve this problem Coumarin derivatives," exact="hymecromone" post="and scoparone which have the ability to reactivate HIV"/>
   <result pre="of latent HIV-1 in latently infected cells by coumarin compounds:" exact="hymecromone" post="and scoparoneCurr. HIV Res.201648449027697031 59SpanakisN.PitirigaV.A review of neuraminidase inhibitor"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7004624\results\search\drugs\results.xml">
   <result pre="has considerably declined. The HIV incidence among clients enrolled in" exact="methadone" post="maintenance treatment programs has decreased from 1% in 2006"/>
   <result pre="high-risk groups[58,59] and people who inject drugs,[60] the daily use" exact="tenofovir" post="disoproxil fumarate/emtricitabine can significantly reduce HIV infection, potentially preventing"/>
   <result pre="doi: 10.1111/j.1537-2995.2011.03078.x.21382047 24.PetersPJPontonesPHooverKWPatelMRGalangRRShieldsJet al.HIV infection linked to injection use of" exact="oxymorphone" post="in Indiana, 2014–2015. N Engl J Med2016; 375:229–239. doi:"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
